The optimal duration and intensity of first-line therapy in metastatic colorectal cancer patients once they have achieved an objective response is controversial. In a molecularly selected RAS and BRAF wild-type (wt) population, this concern is amplified. Once disease control has been achieved with a combination therapy including an anti-EGFR antibody, further exposure both to cytotoxic drugs and targeted therapy might result only in increased toxicity. In unresectable metastatic RAS and BRAF wt colorectal cancer patients, a deintensified therapy could represent a valuable option that might preserve quality of life. We designed a study to compare FOLFIRI/cetuximab to FOLFIRI/cetuximab for eight cycles followed by cetuximab alone in first-line treatment of RAS and BRAF (wt) metastatic colorectal cancer patients.
Pinto, C., Normanno, N., Orlandi, A., Fenizia, F., Damato, A., Maiello, E., Tamburini, E., Di Costanzo, F., Tonini, G., Bilancia, D., Corsi, D. C., Pisconti, S., Ferrau, F., Gori, S., Daniele, B., Zaniboni, A., Soto Parra, H., Frassinetti, G. L., Iaffaioli, R. V., Cassata, A., Zampino, M. G., Repetto, L., Calegari, M. A., Barone, C. A., Phase III study with FOLFIRI + cetuximab versus FOLFIRI + cetuximab followed by cetuximab alone in RAS and BRAF WT mCRC, <<FUTURE ONCOLOGY>>, 2018; 14 (14): 1339-1346. [doi:10.2217/fon-2017-0592] [https://hdl.handle.net/10807/317585]
Phase III study with FOLFIRI + cetuximab versus FOLFIRI + cetuximab followed by cetuximab alone in RAS and BRAF WT mCRC
Orlandi, Armando
;Corsi, Domenico Cristiano;Zaniboni, Alberto;Calegari, Maria Alessandra;Barone, Carlo Antonio
2018
Abstract
The optimal duration and intensity of first-line therapy in metastatic colorectal cancer patients once they have achieved an objective response is controversial. In a molecularly selected RAS and BRAF wild-type (wt) population, this concern is amplified. Once disease control has been achieved with a combination therapy including an anti-EGFR antibody, further exposure both to cytotoxic drugs and targeted therapy might result only in increased toxicity. In unresectable metastatic RAS and BRAF wt colorectal cancer patients, a deintensified therapy could represent a valuable option that might preserve quality of life. We designed a study to compare FOLFIRI/cetuximab to FOLFIRI/cetuximab for eight cycles followed by cetuximab alone in first-line treatment of RAS and BRAF (wt) metastatic colorectal cancer patients.
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
